Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jocelin Jones Molina

Pain Medicine Manati, PR Medical Doctor

NPI 1982141438 CMS profile 7961929

Doctors Center Hospital, Carr. #2 Km 47.7, Manati, PR 00674

Open in the dashboard

General payments

$5,274

47 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jocelin Jones Molina of Manati, PR is reported in the CMS Open Payments database as having received $5,274 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2024 General $36 2
2022 General $4,795 37
2021 General $158 2
2020 General $260 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jocelin Jones Molina
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jocelin Jones Molina were reported at $26. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Jocelin Jones Molina Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $260 $284 $80–$910 $114
2021 $158 $399 $112–$1,219 $132
2022 $4,795 $455 $137–$1,484 $149
2023 $0 $484 $128–$1,495 $160
2024 $36 $498 $131–$1,540 $164
2025 $26 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $4,775 36 payments
  2. Nevro Corp. $260 5 payments
  3. Boston Scientific Corporation $131 2 payments
  4. Pacira Pharmaceuticals Incorporated $52 1 payment
  5. Janssen Pharmaceuticals, Inc $22 1 payment
  6. Sobi, Inc $20 1 payment
  7. Zimmer Biomet Holdings, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $3,788 20 payments
  2. Food and Beverage $1,486 27 payments
Products named General payments · program years 2020–2025
  1. INTELLIS ADAPTIVESTIM $2,155 14 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $1,524 16 payments
  3. RESTORESENSORSURESCAN $997 4 payments
  4. Senza Spinal Cord Stimulation System $260 5 payments
  5. GENERAL PAIN MANAGEMENT $105 1 payment
  6. VANTA ADAPTIVESTIM $93 1 payment
  7. Exparel $52 1 payment
  8. rezum Generator $26 1 payment
  9. XARELTO $22 1 payment
  10. SYNAGIS $20 1 payment
  11. Other $6 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

461

Median for Pain Management: 951

Drug cost

$2,753

Median for Pain Management: $26,034

Branded share of claims

14.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 154 $762
Duloxetine Hcl Generic 46 $566
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 57 $521
Meloxicam Generic 62 $218
Tramadol Hcl Generic 41 $210
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $143
Prednisone Generic 38 $117
Tizanidine Hcl Generic 18 $105
Topiramate Generic 15 $71
Alprazolam Generic 19 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record